Brisbane, Australia, 4 March 2021 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to advise that Medgate AG (“Medgate”) has commenced a three month pilot trial of ResApp’s smartphone-based acute respiratory diagnostic test ResAppDx across its telemedicine services in Switzerland.
Medgate is a leading provider of telehealth services and since 2000, has operated the largest telemedical centre run by doctors in Europe. The group employs over 500 people worldwide, including over 200 physicians. Medgate also operates in Germany, the Philippines, the United Arab Emirates and India.
Commencement of the pilot trial followed a joint development and integration phase (refer ASX announcement: 9 November 2020), which covered technical integration and clinical workflows.
During the integration process, ResApp and Medgate worked collaboratively to conduct comprehensive clinical and technical reviews of ResApp’s technology, detailed mapping of the appropriate user journeys for patients with respiratory disease symptoms, usability testing to deliver a seamless integration pathway, the introduction of automated processes to enhance the patient experience and the development of comprehensive training resources for clinical on boarding to maximise clinician confidence.
During the pilot, ResApp and Medgate will jointly assess the impact of ResAppDx on Medgate’s telehealth service through a number of key performance indicators. Both parties will now enter into broader negotiations pending a successful outcome of the trial.
CEO and Managing Director Dr Tony Keating said: “Medgate is a leading telehealth provider with an established presence in Europe, Asia and the Middle East that constantly strives to bring innovative technologies to market. We are very confident that ResAppDx will provide considerable benefits for Medgate patients, physicians and insurers.
“Medgate has made a strong commitment to ResApp and both parties remain confident of a successful pilot trial. The company has already significantly benefitted from Medgate’s knowledge and insights into telehealth best practice, and we look forward to continuing this work into the future.
“We are excited to see this pilot come to market and look forward to a continued innovative and fruitful relationship with Medgate.”
Dr Andy Fischer, CEO Medgate said: “We are absolutely convinced that the use of new technologies like ResAppDx will enable an advancement of our Digital Health platform. This will benefit our patients by enabling them to be treated conclusively by phone or video in even more cases.”
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp’s regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2021 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257, South Korean Patent No. 1020812410000 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.